RFA-RM-22-014: Technologies and Assays for Therapeutic Genome Editing INDs (U01, Clinical Trial Not Allowed)
Closed
This grant is closed. Who won this program's grants before is below, and similar open grants are at the end of the page. It is in our archive of National Institutes of Health notices from 2022.
National Institutes of Health offered grants to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. Applications closed on July 19, 2022.
From the official notice on Grants.gov, last changed April 11, 2022. Checked November 7, 2026.
- Award amountsNot given on Grants.gov
- Cost sharingNot required
- Funding typeCooperative Agreement
About this NIH notice
- Activity codeU01
- Clinical trialsNot allowed
- Funded byNIAID
- Median yearly award$471,367
- Typical project length4 years
- U01, Research Project Cooperative Agreement. Like an R01, but NIH staff are substantially involved in the work. Other open U01 notices.
Projects funded under RFA-RM-22-014 were run by National Institute of Allergy and Infectious Diseases (NIAID, 5 projects). Contact the program officer at the institute that fits your project before you apply; the notice lists them.
Application due dates, page limits and budget limits are set in the notice. Read RFA-RM-22-014 in the NIH Guide.
Other notices with this title
| Notice | Posted | Deadline | Status |
|---|---|---|---|
| RFA-RM-24-007 | March 22, 2024 | Closed July 26, 2024 | Closed |
Key dates
| Posted | April 11, 2022 |
|---|---|
| Deadline | July 19, 2022 |
| Archived by Grants.gov | August 24, 2022 |
Who can apply
This opportunity was open to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses.
All 15 applicant types the notice lists
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- For profit organizations other than small businesses
- Small businesses
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
Is this a realistic fit?
- Most of the program's money (72% over five years) went to colleges and universities.
- No cost sharing or match is required.
What the grant funds
The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications on the optimization and characterization of technologies and assays with the potential for utilization and adoption in regulatory submissions of genome editing therapeutics.
Funded under RFA-RM-22-014 so far
NIH funded 5 projects under RFA-RM-22-014 in fiscal 2023 to 2025, at 4 institutions. The median yearly award was $471,367.
| Project | Institution | Fiscal year | Award |
|---|---|---|---|
| Genome sequencing for evaluating the efficacy, specificity, and safety of human genome editing | Washington University | 2025 | $458,717 |
| Sensitive, unbiased, high-throughput, cellular GUIDE-seq-2 genome-wide activity assay for therapeutic genome editing INDs | St. Jude Children's Research Hospital | 2025 | $479,100 |
| Utility of Human Organoids for Safety and Efficiency Evaluations of Genome Editing Therapeutics | University of Washington | 2025 | $341,841 |
| Ultra-sensitive, unbiased, high-throughput, biochemical CHANGE-seq genome-wide activity and gRNA sequencing assays for therapeutic genome editing INDs | St. Jude Children's Research Hospital | 2025 | $479,100 |
| A Modality-Agnostic Potency Assay Enabling Both Ex Vivo and In Vivo Genome Editing Therapeutics for Sickle Cell Disease | University of California Berkeley | 2025 | $470,454 |
Who has won Trans-NIH Research Support grants before
From fiscal 2021 to 2025, Trans-NIH Research Support (93.310) awarded $5.9 billion across 4,433 grant awards, an average of $1.3 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| Duke University | North Carolina | 66 | $219 million |
| The Leland Stanford Junior University | California | 104 | $176 million |
| University of Pittsburgh - of the Commonwealth System of Higher Education | Pennsylvania | 82 | $154 million |
| The Johns Hopkins University | Maryland | 95 | $152 million |
| Yale Univ | Connecticut | 85 | $149 million |
Applying now
This notice no longer takes applications. Agencies often post the same opportunity again under a new number, so check the program's notices on Grants.gov and the similar open grants below.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is RFA-RM-22-014 still open?
No. It closed on July 19, 2022.
Who can apply for Technologies and Assays for Therapeutic Genome Editing INDs (U01, Clinical Trial Not Allowed)?
National Institutes of Health accepted applications from nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. The notice adds further conditions, so read its eligibility section.
What is the deadline for Technologies and Assays for Therapeutic Genome Editing INDs (U01, Clinical Trial Not Allowed)?
Closed July 19, 2022. Applications are no longer accepted; the program's newer notices are on this page when there are any.
Who has been funded under RFA-RM-22-014?
NIH RePORTER lists 5 projects funded under RFA-RM-22-014 in fiscal 2023 to 2025, at 4 institutions. The most were at St. Jude Children's Research Hospital, Washington University, University of Washington.
Who has won Trans-NIH Research Support grants before?
The largest recipients over five fiscal years were Duke University, The Leland Stanford Junior University, University of Pittsburgh - of the Commonwealth System of Higher Education. The program made 4,433 awards worth $5.9 billion in that time.
Similar open grants
- Single Source for the Continuation of the Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) Scientific and Data Research Center (U01 Clinical Trial Required)
- Single Source for the Continuation of the Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Center (Collaborative U01 Clinical Trial Not Allowed)
- Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)
- Single Source for the Continuation of the Physiology of the Weight Reduced State (POWERS) Study (U01- Clinical Trials Required)
- Canine Cancer Immunotherapy Network (K9CIN; U01 Clinical Trial Not Allowed)
- Opportunities for Collaborative Research with the NIH Intramural Research Program (U01 Clinical Trial Optional)